- Home
- CAG vs KYMR Comparison
CAG vs KYMR Comparison
Compare CAG & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | KYMR |
|---|---|---|
| Founded | 1919 | 2015 |
| Country | United States | United States |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.4B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAG | KYMR |
|---|---|---|
| Price | $13.57 | $99.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 26 |
| Target Price | $16.88 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 14.3M | 793.3K |
| Earning Date | 04-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 9.84% | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,500,000,000.00 | $39,211,000.00 |
| Revenue This Year | N/A | $10.61 |
| Revenue Next Year | N/A | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.53 | $36.88 |
| 52 Week High | $21.37 | $105.00 |
Technical Indicators
Market Signals| Indicator | CAG | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 74.83 |
| Support Level | $12.53 | $76.40 |
| Resistance Level | $14.06 | $103.00 |
| Average True Range (ATR) | 0.45 | 4.66 |
| MACD | 0.07 | 2.50 |
| Stochastic Oscillator | 68.52 | 84.32 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.